188 related articles for article (PubMed ID: 22297896)
1. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy.
Pedroso JL; Braga-Neto P; Dutra LA; Barsottini OG
Arq Neuropsiquiatr; 2011 Dec; 69(6):993. PubMed ID: 22297896
[No Abstract] [Full Text] [Related]
2. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Abele M; Weller M; Mescheriakov S; Bürk K; Dichgans J; Klockgether T
Neurology; 1999 Mar; 52(4):857-9. PubMed ID: 10078741
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia.
Nanri K; Okita M; Takeguchi M; Taguchi T; Ishiko T; Saito H; Otsuka T; Mitoma H; Koizumi K
Intern Med; 2009; 48(10):783-90. PubMed ID: 19443972
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Autoantibodies and the Efficacy of Immunotherapy for Autoimmune Cerebellar Ataxia.
Nanri K; Okuma M; Sato S; Yoneda M; Taguchi T; Mitoma H; Yamada J; Unezaki S; Nagatani T; Otsubo S; Sugawara M; Tanaka N; Mizusawa H
Intern Med; 2016; 55(5):449-54. PubMed ID: 26935362
[TBL] [Abstract][Full Text] [Related]
5. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
8. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Virgilio R; Corti S; Agazzi P; Santoro D; Lanfranconi S; Candelise L; Bresolin N; Comi GP; Bersano A
J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):95-6. PubMed ID: 19091718
[No Abstract] [Full Text] [Related]
9. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
10. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.
Vianello M; Tavolato B; Armani M; Giometto B
Cerebellum; 2003; 2(1):77-9. PubMed ID: 12882238
[TBL] [Abstract][Full Text] [Related]
11. [Autoantibodies associated with autoimmune-mediated cerebellar ataxia].
Mitoma H; Nanri K
Brain Nerve; 2013 Apr; 65(4):355-64. PubMed ID: 23568983
[TBL] [Abstract][Full Text] [Related]
12. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
13. Anti-glutamic acid decarboxylase antibody positive neurological syndromes.
Tohid H
Neurosciences (Riyadh); 2016 Jul; 21(3):215-22. PubMed ID: 27356651
[TBL] [Abstract][Full Text] [Related]
14. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment.
Nociti V; Frisullo G; Tartaglione T; Patanella AK; Iorio R; Tonali PA; Batocchi AP
Eur J Neurol; 2010 Jan; 17(1):e5. PubMed ID: 19906270
[No Abstract] [Full Text] [Related]
15. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
16. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
17. [A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative].
Birand B; Cabre P; Bonnan M; Olindo S; Smadja D
Rev Med Interne; 2006 Aug; 27(8):616-9. PubMed ID: 16797794
[TBL] [Abstract][Full Text] [Related]
18. Lesson of the month 2: Autoimmune sequelae of anti-GAD antibodies - thinking outside the box.
Ward RJ; Varughese GI; Jose B; Abraham RJ
Clin Med (Lond); 2017 Oct; 17(5):473-474. PubMed ID: 28974603
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
Saiz A; Arpa J; Sagasta A; Casamitjana R; Zarranz JJ; Tolosa E; Graus F
Neurology; 1997 Oct; 49(4):1026-30. PubMed ID: 9339684
[TBL] [Abstract][Full Text] [Related]
20. Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
Jazebi N; Rodrigo S; Gogia B; Shawagfeh A
J Neuroimmunol; 2019 Jul; 332():135-137. PubMed ID: 31015081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
